Pharmacyte Biotech Inc 's ROA from the first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Pharmacyte Biotech Inc 's ROA in the first quarter of 2026?
Pharmacyte Biotech Inc recorded a cumulative net loss of $-16 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -33.32%.

However, within the Healthcare sector 524 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2026 from 3521 to 3832.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jul 31 2026) I. Quarter	(Apr 30 2026) IV. Quarter	(Jan 31 2026) III. Quarter	(Oct 31 2025) II. Quarter	(Jul 31 2025) I. Quarter
Y / Y Total Assets Change	-20.69 %	-17.1 %	-5.85 %	-0.74 %	-35.3 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-16	-20	-6	-10	-5
Return On Assets (TTM)	-33.32 %	-38.14 %	-11.97 %	-18.53 %	-8.28 %
PMCB's Total Ranking	# 3832	# 3521	# 3216	# 99	# 145
Total Assets (TTM) in million	37	47	56	56	46
Seq. Total Assets Change	-21.48 %	-17.1 %	0.14 %	21.66 %	-17.92 %
Seq. Net Income Change	-	-	-	-	-

PMCB's 5 Years Annual ROA >> Back to PMCB Management Effectiveness >> Compare PMCB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 63
Sector	# 525
Overall	# 4296

Return On Assets Statistics
High	Average	Low
44.19 %	-82.38 %	-527.5 %
(Apr 30 2025)		(Apr 30 2014)

Financial Statements
Pharmacyte Biotech Inc 's Assets	$ 37 million	PMCB's Balance sheet
Pharmacyte Biotech Inc 's Income	$ -5 million	Quarterly PMCB's Income Statement
PMCB's Income by Division		See PMCB's Income by Division

Annual Return On Assets	(Apr 30 2026) FY 2026	(Apr 30 2025) FY 2025	(Apr 30 2024) FY 2024	(Apr 30 2023) FY 2023	(Apr 30 2022) FY 2022
Y / Y Total Assets Change	0.69 %	-5.85 %	-19.34 %	-18.05 %	1123.95 %
Total Assets in million	57	56	60	74	91
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-19	27	-2	-4	-4
Annual Return On Assets	-34.21 %	47.09 %	-3.65 %	-5.81 %	-4.68 %

PMCB's 5 Years Annual ROA >> Back to PMCB Management Effectiveness >> Compare PMCB ROA to its Competitors

More Return On Assets Ratios
PMCB's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PMCB's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PMCB's Competitors
Subscribers only: Roa for Pharmacyte Biotech Inc 's Suppliers
Subscribers only: Return On Assets for PMCB's Customers

You may also want to know
PMCB's Roi	PMCB's Inventory Turnover Ratio	PMCB's Growth Rates	PMCB's Dividend Comparisons
	PMCB's Profitability Ratios	PMCB's Asset Turnover Ratio	PMCB's Dividend Growth
PMCB's Roe	PMCB's Valuation Ratios	PMCB's Financial Strength Ratios	PMCB's Dividend Payout Ratio

Companies with similar Return On Assets at Jul 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-15T12:00:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.